Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
January 26, 2016 07:05 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Added to NASDAQ Biotechnology Index
December 15, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
October 07, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Label Expansion Indication
March 26, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...